Cutaneous Lichen Amyloidosis When Topical DMSO Has Not Worked

This protocol addresses patients with cutaneous lichen amyloidosis in whom initial treatment with topical DMSO has failed to achieve adequate symptom control. When the targets of that first-line regimen are not met, a structured next-line approach is indicated.

Previous Treatment — Insufficient Response

Topical DMSO (applied daily, with intermittent maintenance once pruritus was partially reduced) was the prior regimen. The goals it was expected to meet — significant reduction of pruritus, pigmentation, and papules — were not achieved, triggering escalation to this protocol.

Next-Line Approach (Partial Overview)

The next step centres on a phototherapy-based strategy. More than one modality within this category may be applicable — the specific selection, sequencing, and clinical algorithm are set out in the full protocol.

Treatment Goals

Resolution of pruritus and reduction of papules in lichen amyloidosis.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4103/pigmentinternational.pigmentinternational_

Phototherapy is an alternative safe option in the management of PLCA.
NbUVB therapy was reported to be very effective in both MA and LA.
PUVA, topical psoralen with Ultraviolet A was also found to be of benefit, especially with regards to the resolution of pruritus in LA.
Re-PUVA, a combination of acitretin with bath PUVA, was used with success to reduce the pruritus and the papules in LA.

View source ↗